6.6.2 Bisphosphonates and other drugs affecting bone metabolism
MHRA Safety Update: Bisphosphonates: atypical femoral fractures
MHRA Safety Update: Bisphosphonates: osteonecrosis of the jaw
MHRA Safety Update: Bisphosphonates: atrial fibrillation
For guidance on drug treatment of osteoporosis see primary and secondary prevention pathways
NICE NG101: Early and locally advanced breast cancer: diagnosis and management
For daily dosing
| Pack |
|---|
| 28 tablet |
For weekly dosing
| Pack |
|---|
| 4 tablet |
MHRA safety update: osteonecrosis of the external auditory canal
| Pack |
|---|
| 1 pre-filled disposable injection |
This formulation is not for use in osteoporosis
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 tablet |
| Pack |
|---|
| 1 pre-filled disposable injection |
Daily dose
| Pack |
|---|
| 28 tablet |
Daily dose for Paget's disease of bone
| Pack |
|---|
| 28 tablet |
Weekly dose
| Pack |
|---|
| 4 tablet |
Adjuvant treatment in post-menopausal women with breast cancer at high risk of recurrence. For use in accordance with NICE NG101 where zoledronate infusion is declined due to patient preference or side effects.
| Pack |
|---|
| 60 tablet |
These products should only be administered by staff trained to administer intravenous infusions in a hospital or specialist centre
For cancer indications only
For first line adjuvant treatment in post-menopausal women with breast cancer at high risk of recurrence in accordance with NICE NG101
| Pack |
|---|
| 1 vial |
For osteoporosis only
| Pack |
|---|
| 1 bottle |
- First Line Drugs
- Second Line Drugs
- Specialist Initiated Drugs
- Specialist Only Drugs
- Mixed Status